Cargando…
A comparison between on-demand usage of rFVIIa vs prophylaxis use of emicizumab in high titer inhibitory hemophilia A patients in Iran: A cost–utility analysis
BACKGROUND: Hemophilia A (HA) is an inherited X-linked bleeding disease with costly treatment, especially for high titer inhibitory patients. Emicizumab, a new humanized bispecific antibody, has been approved for use to prevent or reduce the frequency of bleeding episodes in HA patients with inhibit...
Autores principales: | Saiyarsarai, Parisa, Robabpour Derakhshan, Atefeh, Khedmati, Jamaleddin, Eshghi, Peyman, Seyedifar, Meysam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500655/ https://www.ncbi.nlm.nih.gov/pubmed/34622828 http://dx.doi.org/10.1097/MD.0000000000027303 |
Ejemplares similares
-
Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence
por: Linari, Silvia, et al.
Publicado: (2020) -
Bioengineering of rFVIIa Biopharmaceutical and Structure Characterization for Biosimilarity Assessment
por: Montacir, Othman, et al.
Publicado: (2018) -
Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage
por: Aggarwal, Anita, et al.
Publicado: (2004) -
Renal thromboembolism during treatment with recombinant activated factor VII (rFVIIa) in a child with hemophilia B with factor IX inhibitors
por: Milošević, Danko, et al.
Publicado: (2014) -
Regional variation of the off-licence use of rFVIIa for patients with uncontrolled haemorrhage in England
por: Spivey, MH, et al.
Publicado: (2010)